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Genomic heterogeneity of multiple
synchronous lung cancer
Yu Liu1,*, Jianjun Zhang2,3,*, Lin Li1,4,*, Guangliang Yin5,*, Jianhua Zhang6,*, Shan Zheng4, Hannah Cheung2,
Ning Wu7, Ning Lu4, Xizeng Mao6, Longhai Yang8, Jiexin Zhang9, Li Zhang7, Sahil Seth6, Huang Chen1,
Xingzhi Song6, Kan Liu7, Yongqiang Xie4, Lina Zhou7, Chuanduo Zhao8, Naijun Han1, Wenting Chen1,
Susu Zhang1, Longyun Chen5, Wenjun Cai5, Lin Li5, Miaozhong Shen5, Ningzhi Xu10, Shujun Cheng1,
Huanming Yang5, J. Jack Lee11, Arlene Correa12, Junya Fujimoto13, Carmen Behrens13, Chi-Wan Chow13,
William N. William3, John V. Heymach3, Waun Ki Hong3, Stephen Swisher12, Ignacio I. Wistuba13,
Jun Wang5,14,**, Dongmei Lin4,**, Xiangyang Liu8,**, P. Andrew Futreal2,15,** & Yanning Gao1,**
Multiple synchronous lung cancers (MSLCs) present a clinical dilemma as to whether
individual tumours represent intrapulmonary metastases or independent tumours. In this study
we analyse genomic proﬁles of 15 lung adenocarcinomas and one regional lymph node
metastasis from 6 patients with MSLC. All 15 lung tumours demonstrate distinct genomic
proﬁles, suggesting all are independent primary tumours, which are consistent with
comprehensive histopathological assessment in 5 of the 6 patients. Lung tumours of the same
individuals are no more similar to each other than are lung adenocarcinomas of different
patients from TCGA cohort matched for tumour size and smoking status. Several known
cancer-associated genes have different mutations in different tumours from the same patients.
These ﬁndings suggest that in the context of identical constitutional genetic background and
environmental exposure, different lung cancers in the same individual may have distinct
genomic proﬁles and can be driven by distinct molecular events.
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L
ung cancer is a heterogeneous disease, with genomic and
phenotypic features that differ between different patients
and even between different regions of a tumour. Substantial
inter-tumour heterogeneity, probably reﬂecting distinct genetic
backgrounds and different carcinogen exposures in different
patients with lung cancer, has been well documented1,2. On the
other hand, recent studies from our group and others on non-
small cell lung cancer have shown that the majority of mutations
are present in all regions of a single tumour, suggesting limited
intratumour heterogeneity3,4. Like different regions of the same
tumour, multiple synchronous lung cancer (MSLC), multiple
tumours arising in different areas of the lung parenchyma within
a single patient, share a constitutional genetic background and
exposure history. Previous studies have reported differences in
certain cancer gene mutations and chromosome aberrations
between different MSLCs5–8. The comprehensive genomic
heterogeneity of MSLCs has not been well characterized but
may be critical to diagnosis and appropriate treatment.
MSLCs may represent hematogenous metastases from a single
primary cancer, local spread of a single primary lesion or multiple
individual primary cancers. In 2007, the American College of
Chest Physicians (ACCP) classiﬁed MSLCs of the same histology
into satellite nodules (same lobe, no systemic metastases), multiple
primary lung cancers (different lobes, no N2–N3 lymph node
involvement or systemic metastases) and hematogenously spread
pulmonary metastases (different lobes, N2–N3 lymph node
involvement)9. Hematogenously spread pulmonary metastases
and locally spread satellite nodules are generally believed to
derive from corresponding primary tumours10. However, the
clonal origin of multiple primary lung cancers is a subject of
debate, with respect to whether they arise either independently
from different progenitor cells, in line with the ﬁeld cancerization
concept11, or from a single clonal event resulting in a tumour that
subsequently spreads. Previous studies using targeted molecular
markers obtained conﬂicting results6,7,12.
To determine the genomic heterogeneity of MSLCs and assess
the clonal relationships between different tumours within the
same patients, we perform whole-genome sequencing (WGS) or
whole-exome sequencing in combination with microarray-based
comparative genomic hybridization (CGH) on 16 tumour
samples (15 lung tumours (all adenocarcinomas) and one
regional lymph node metastasis) from six patients with MSLCs.
Five patients had satellite nodules, and one had hematogenously
spread pulmonary metastasis according to the ACCP criteria
(Table 1). For all 15 lung tumours, comprehensive genomic
analysis revealed distinct genomic proﬁles, suggesting all were
primary tumours.
Results
Somatic point mutations. In total, 1,127 nonsynonymous coding
and splice site mutations were detected (Supplementary Tables 2
and 3). Of those mutations, 956 were subjected to Sequenom’s
MassARRAY mass spectrometry platform or Sanger sequencing
validation, and 876 (92%) were validated (Supplementary Table 4
and Supplementary Fig. 2). The remaining 171 mutations were
not subjected to validation because of insufﬁcient remaining
DNA. Each of these 171 mutations was detected in only one
tumour. Of the 662 nonsynonymous coding and splice site
mutations called by both MuTect13 and VarScan14, 645 (97%)
were validated.
No shared mutations were detected between different tumours
from patient 2, 3 and 4 (a total of 167 mutations in six tumours),
suggesting that these patients had multiple primary lung cancer
(Fig. 1). In patient 1, tumour 3 (T3) and a lymph node metastasis
shared 52 (26%) of 198 mutations, including a KRAS (p.G12V)
mutation and a STAG2 nonsense mutation (p.R305X), suggesting
that the tumour metastasized to the lymph node (Figs 1 and 2).
No other mutations were shared in the remaining samples from
patient 1, indicating that the three lung tumours in this patient
were independent primary tumours.
An EGFR p.L858R mutation was the only mutation shared by
all three tumours of patient 6 (Figs 1 and 2). This is a known
hotspot mutation and accounts for more than 40% of EGFR
mutations reported in Asian lung adenocarcinoma patients15.
The ﬁnding of a single prevalent hotspot mutation, however,
provides limited information about tumours’ independence.
Indeed, comparison of EGFR p.L858R prevalence in this series
(considering each tumour as being from a unique patient) to that
Table 1 | Clinical characteristics and sequencing information of the six patients with multiple synchronous lung cancers.
Patient ID Tumour
ID
Size
(cm)
Location Histology Node
staging
ACCP Comprehensive
histopathological
analysis36
Genomic
proﬁling
Adjunct
therapy
Follow-up
(months)
Recurrence Smoking
status
Sequencing/
depth
Patient 1 Pa1T1 1.8 RUL ADC N2 Hematogenously
spread pulmonary
metastases
Primary Primary Chemotherapy 42 Yes Former
smoker
WGS/37
Pa1T2 1.8 RUL ADC WGS/35
Pa1T3 3.6 RLL ADC WGS/35
Pa1LN 2 Mediastinum ADC WGS/35
Patient 2 Pa2T1 2 LUL ADC N0 Satellite nodules Primary Primary No 33 No Non-
smoker
WES/55
Pa2T2 3.1 LUL ADC WES/74
Patient 3 Pa3T1 3.5 RLL ADC N0 Satellite nodules Primary Primary No NA NA Former
smoker
WES/74
Pa3T2 3.5 RLL ADC WES/54
Patient 4 Pa4T1 0.6 RUL ADC N0 Satellite nodules Primary Primary No 38 No Non-
smoker
WES/51
Pa4T2 1 RUL ADC WES/56
Patient 5 Pa5T1 2 RUL ADC N0 MPLC with
satellite nodules
Metastasis Primary No 35 No Non-
smoker
WES/57
Pa5T2 2 RUL ADC WES/56
Pa5T3 0.6 RML ADC WES/64
Patient 6 Pa6T1 0.8 RUL ADC N0 MPLC with
satellite nodules
Primary Primary No 41 No Non-
smoker
WES/52
Pa6T2 0.5 RUL ADC WES/58
Pa6T3 1.5 RML ADC WES/71
ADC, adenocarcinoma; LUL, left upper lobe; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe; WGS, whole genome sequencing; WES, whole-exome sequencing.
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Figure 1 | Similarity among different lesions rising from a single patient with MSLC based on somatic mutation analysis. (a) Heatmap of validated
mutations shared by 16 intra-thoracic adenocarcinomas of six patients with MSLC. The number of total mutations identiﬁed in each tumour (T) and the
number of mutations shared by any pair of lesions are shown. Tumours from the same patients are identiﬁed by blue boxes. LN, lymph node metastasis.
(b) Venn diagram illustrating the distributions of validated mutations in the 16 lesions. Shared mutations were deﬁned as identical nucleotide substitutions
at the same genomic coordinates.
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in a large cohort of Chinese lung adenocarcinoma patients15
showed no enrichment in this series (6 mutations in 15 tumours
(the lymph node was not included) in our study versus 111
mutations in 437 patients in the larger cohort, P¼ 0.23 by
Fisher’s exact test). Thus, with no other evidence of shared
mutations, the data suggest that patient 6 likely had three primary
tumours carrying independent EGFR p.L858R mutations.
In patient 5, two somatic mutations were concordant among
the three tumours sequenced: an EGFR p.L858R mutation shared
by tumours 1 and 2, and an ARHGAP35 p.E25K mutation shared
by tumours 1 and 3 (Figs 1 and 2). As with patient 6, the presence
of single EGFR p.L858R does not provide conclusive evidence that
tumours 1 and 2 of patient 5 were clonally related. ARHGAP35
p.E25K was the only shared mutation of the 171coding mutations
identiﬁed in tumours 1 and 3 of patient 5, which suggests two
possibilities: (i) one of the two tumours was a metastasis of the
other; or (ii) the two tumours arose independently, each acquiring
an ARHGAP35 p.E25K mutation during cancer development.
The data from patient 1 and previous studies4,16,17 suggest that
the proportion of mutations shared between primary cancers
and metastases is markedly higher than the proportion
observed in patient 5 and that the observed proportion does
not support a primary/metastasis relationship between tumours 1
and 3 of patient 5. To test the possibility that tumours 1 and 3
acquired ARHGAP35 p.E25K independently, we compared our
data with The Cancer Genome Atlas (TCGA) data for a series of
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Figure 2 | Nonsynonymous point mutations and copy number changes in known cancer genes in 16 intra-thoracic lesions of six patients with MSLC.
Copy number changes were deﬁned on the basis of segment log2 ratios derived from microarray-based CGH, with log2 ratios 40.3 categorized as
copy number gains and log2 ratios o0.3 categorized as copy number losses. AA, amino acid; LN, lymph node metastasis; NA, not applicable;
T, tumour number.
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single primary tumours from 35 unrelated lung adenocarcinoma
patients matched for tumour size and smoking status2.
The sharing of one exonic mutation (excluding mutations in
genes frequently mutated in lung adenocarcinomas) was no more
likely in our series than in the TCGA cohort: 1/884 exonic
mutations shared between any tumour pairs in this series versus
20/8,413 exonic mutations shared between any tumour pairs in
the TCGA cohort (P¼ 0.72 by Fisher’s exact test, Supplementary
Table 5). Taken together, the data suggest the three tumours of
patient 5 were likely independent primary tumours.
To maximize the opportunity to uncover evidence of tumour
relatedness in our MSLC cohort, we expanded the mutation data
set to include all validated mutations plus all mutations that were
called by both VarScan13 and MuTect14. Since the validation rate
for nonsynonymous mutations that were called by both algorithms
was 97%, an extrapolation to mutations that were not submitted
to validation could be made with some conﬁdence. Using
the expanded list of 51,470 mutations, we did not identify
any additional mutations shared by different tumours within the
same patient (Supplementary Fig. 3), further suggesting that all 15
lung tumours of the six patients were independent primary
tumours.
We then compared the exonic point mutations in the 16 MSLC
lesions in our cohort and those in the 35 unrelated lung
adenocarcinomas in the TCGA study2, conservatively restricting
our comparison to only T1–T2a tumours from never smokers
and light smokers to make the cohorts more comparable. With
the exception of tumour 3 and the associated lymph node
metastasis in patient 1, each tumour shared no more than one
mutation with another tumour (Supplementary Table 6).
These data indicated that the MSLCs in our series were no
more similar to each other than were similarly staged tumours
from unrelated patients.
Known cancer gene mutations. We next examined the pattern of
known cancer gene mutations in our series. We deﬁned cancer
gene mutations as nonsynonymous mutations identical to those
previously reported in known cancer genes or truncating mutations
in known tumour suppressor genes18–23. In total, 14 known cancer
gene point mutations were identiﬁed in at least one tumour each
(Fig. 2). With the exception of the EGFR mutations mentioned
above, no known cancer gene mutations were shared between any
two tumours from the same patients, suggesting that different
tumours in the same patients may have been driven by different
molecular events. On the other hand, three cancer genes
demonstrated different mutations in different tumours of the
same patients. In patient 1, tumour 3 (and the associated lymph
node metastasis) harboured a KRAS p.G12V mutation, whereas
tumour 1 had a KRAS p.G12A mutation. Different mutations were
also observed in STK11 in patient 1 (a missense mutation p.K78N
in tumour 1 and a nonsense mutation p.Q37X in tumour 2) and in
EGFR in patient 4 (p.L858R in tumour 1 and p.S229C in tumour
2). In addition, two different PIK3CA mutations, p.G1007R and
p.H1047R, were found in tumour 3 of patient 5.
Mutation spectra and mutation signature. Our series of samples
afforded the opportunity to explore mutational processes in the
context of independent tumours arising on a ﬁxed genetic
background and with shared exposure. Consistent with previous
studies18,19,23,24, mutation spectra differed between smokers and
non-smokers. Five of six tumours (including the metastatic
lymph node) from the two former smokers (patients 1 and 3)
had predominantly C4A substitutions, while eight of ten
tumours from the four never smokers had largely C4T
mutations. Discordant mutational spectra were observed
between same-patient tumours in all six patients, and the
difference was statistically signiﬁcant in patients 1, 2 and 5
(Supplementary Fig. 4), suggesting that different mutational
processes were involved during the development of different
tumours within the same patients. In addition, an apolipoprotein
B mRNA editing enzyme, catalytic polypeptide-like (APOBEC)-
mediated process25–27 was found to contribute substantially to
the mutations. However, the contribution varied between same-
patient tumours. On average, 26% of the mutations showed an
APOBEC-mediated pattern (C4T/G at TpCpW sites, where W is
A or T). APOBEC signature enrichment was found in 15 of the 16
tumours, and the enrichment odds ratios were signiﬁcant in
7 tumours of four patients (Supplementary Fig. 5).
For patient 1,WGS provided sufﬁcient data for a more detailed
mutation signature analysis27. Although all tumours of patient 1
showed similar mutation signatures as a group (driven mainly
by the smoking-related C4A substitutions), the mutation
signatures differed substantially between the individual tumours
(Supplementary Fig. 6). However, tumour 3 (the largest tumour)
and the associated lymph node metastasis had almost exactly
the same mutation signatures, with overrepresentation of the
presumptive APOBEC signature. This ﬁnding is consistent
with recent evidence that APOBEC processes may be operative
preferentially at a later stage in lung cancer progression3,4.
These results suggest that, although the same dominant
mutational processes may operate in different MSLC tumours
during tumorigenesis (such as the mutational process driven by
smoking-associated carcinogens), distinct mutational processes
can be superimposed on this background in different tumours of
the same patient.
Copy number aberration. Using microarray-based CGH, we
generated somatic copy number aberration (SCNA) proﬁles of all
tumours. In general, SCNAs were relatively few (Supplementary
Fig. 7) compared with those in previous studies1,2,18, perhaps
due to the small sizes of the tumours and the fact that all patients
were never smokers or former light smokers. Similar to the
patterns of point mutations discussed above, the SCNA proﬁles of
different tumours from the same patients were very different,
consistent with the independent nature of these tumours
(Supplementary Fig. 7). Further, ampliﬁcations and deletions of
known cancer genes21 were identiﬁed in the 15 lung tumours and
the lymph node metastasis, but none was shared between
different tumours of the same patients (Fig. 2).
Indels and structural variation. Eleven exonic small insertions/
deletions (indels) were identiﬁed (none was subjected to
validation because of insufﬁcient DNA). Each indel was detected
in no more than one tumour (Supplementary Tables 2 and 3),
consistent with the independent, primary nature of these
tumours. We were also able to evaluate genomic rearrangement
proﬁles of the four lesions of patient 1 by WGS. With the
exception of two deletions shared by tumour 3 and the associated
lymph node metastasis, no common structural variants
were observed between any two lesions, further supporting
independent origin of the tumours investigated (Supplementary
Fig. 8 and Supplementary Table 7).
Discussion
MSLCs have been reported to account for 0.2–8% of lung
cancers10,12,28,29, with increasing frequency of detection due
to wider implementation of multislice spiral computed
tomography, ﬂuorescence endoscopy and positron emission
tomography30,31. In this study, we performed comprehensive
genomic proﬁling of 15 multiple synchronous lung
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adenocarcinomas and one lymph node metastasis from 6 patients.
Despite shared genetic background and exposure history, all
same-patient lung tumours had distinct genomic proﬁles,
including somatic point mutations, copy number aberrations,
chromosomal structural variations and even mutational spectra.
Tumours of the same individuals were no more similar to each
other than lung adenocarcinomas of different patients (TCGA
data) matched for tumour size and patient smoking status. These
data provide evidence that multiple mutational processes may be
in play during the development of independent lung tumours
within the same individual subjected to common exposures on
the same constitutional genetic background.
In addition, several cancer genes had different mutations in
different tumours within the same patients. This ﬁnding is
reminiscent of intratumour heterogeneity observed for clear cell
renal cell carcinomas32, with different mutations in the same
cancer gene found in different subclones of the primary tumour
suggesting convergent selection. Although our sample size was
small, these results suggest that even in the context of identical
genetic background and environmental exposure, the development
of multiple primary lung adenocarcinomas can be driven by
distinct molecular events in different tumours, with possible
selection constraints around certain genes/pathways that are
critical for carcinogenesis in speciﬁc patients.
MSLCs could be multiple primary tumours that are potentially
curable or intrapulmonary metastases that could be taken as an
indication of unresectable disease. Many attempts have been made
to distinguish these clinical entities. Martini–Melamed criteria33
and ACCP guidelines9 are widely adapted clinical guidelines
although they are rather empirical with little supporting molecular
evidence. In this study, we proﬁled 6 patients who were all deﬁned
as clinically metastatic (intrapulmonary metastasis or satellite
nodules) by ACCP guidelines (therefore, may be otherwise
excluded from curative therapies). However, genomic proﬁling
suggested that all 6 patients in fact had multiple primary
tumours. With a minimum follow-up of 33 months post surgery,
none of the patients with satellite nodules has relapsed, while the
patient with hematogenously spread pulmonary metastasis (patient
1) relapsed 42 months after surgery. Previous studies have
demonstrated a slightly shorter survival in patients with satellite
nodules compared with patients without satellite nodules matched
for primary tumour size, lymph node and metastatic stage34. Our
data suggest that a substantial proportion of tumours categorized
as hematogenously spread pulmonary metastases and satellite
nodules may instead be multiple primary tumours. To improve the
diagnostic accuracy of MSLCs, pioneering studies led by
Travis et al. have investigated comprehensive histologic
assessment and have shown promising results8,35,36. Using
similar approach, we were able to accurately identify 5 of the 6
patients (Supplementary Table 1) conﬁrming that comprehensive
histologic assessment is highly valuable to distinguish multiple
primary tumours from intrapulmonary metastases in majority of
patients. However, morphology is presumably controlled by
complex molecular mechanisms, of which our knowledge is
rudimentary. Tumours can change their histologic appearance
from one to another. Thus, the morphology similarity between
different tumours could be suggestive but not conclusive. On the
other hand, as shown in this study, with the caveat of the small
sample size fully acknowledged, multiple primary tumours have
distinct genomic proﬁles, while metastatic lesions usually retain a
signiﬁcant fraction of genomic aberrations from the founding
primary tumours16,17,37. Therefore, comprehensive genomic
proﬁling at the exome level, can provide pivotal information to
clinical and histologic assessment to accurately distinguish multiple
primary lung cancers from intrapulmonary metastases.
Application of genomic proﬁling in the clinical setting of staging
patients with MSLCs should be explored in a larger cohort to
conﬁrm the utility suggested here. If corroborated, genomic
proﬁling may prove an important component of a more precise
approach in managing patients presenting with MSLC.
Methods
Patients. Surgical specimens and peripheral blood samples were collected from six
patients who were diagnosed with pathologically conﬁrmed multiple synchronous
lung adenocarcinomas, with two or three tumours in the same lung, and treated at
the Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing,
China. Tumour sizes ranged from 0.5 to 3.6 cm according to pathology reports. All
patients were free of extrathoracic metastasis. Patient 1 had metastasis to a med-
iastinal lymph node, but no other patient had lymph node involvement. None of
the patients had pre-operative chemotherapy or radiation therapy. Four patients
were never smokers, and two were former smokers. The patients’ clinical char-
acteristics are listed in Table 1, and tumour characteristics are shown in
Supplementary Table 1 and Supplementary Fig. 1. The collection and analysis of
patient samples were approved by the Ethics Committee of the Cancer Institute
and Hospital, Chinese Academy of Medical Sciences. Informed consent was
obtained from all patients.
Sample collection and processing. After resection, ten 10mm fresh frozen sections
for each tumour sample or ten 10mm formalin-ﬁxed parafﬁn-embedded sections for
the regional lymph node metastasis were collected. Haematoxylin–eosin-stained
slides (Supplementary Fig. 1B) were reviewed by experienced lung cancer patholo-
gists to determine the histomorphological subtype and the proportion of malignant
cells relative to nonmalignant stromal (inﬂammatory, vascular and ﬁbroblast) cells.
In addition, tumour cell viability was addressed by examining the presence of
necrosis in the tissues. Tumour cells were enriched by having a pathologist scrape
tumour tissues from each slide. Genomic DNA was then extracted from all samples,
and matched peripheral blood leukocytes were used as a germline DNA control.
Whole-genome sequencing. Genomic DNAs were fragmented into 500-bp
segments by using the Covaris (Woburn, MA) E210 instrument. The double-
stranded DNA fragments consisted of 30 or 50 overhangs. T4 DNA polymerase and
Klenow enzyme (Invitrogen, Life Technologies, Grand Island, NY) were then used
to convert the overhangs into blunt ends. An A base was added to the 30-end of the
blunt phosphorylated DNA fragments, which was ligated with adapters on both
ends. The correctly ligated products were puriﬁed by agarose gel electrophoresis
and then with the QIAquick Gel Extraction Kit (Qiagen, Valencia, CA). DNA
fragments with adapter molecules on both ends were selected and ampliﬁed. After
PCR using primers that anneal to the ends of the adapters, the products were
checked and puriﬁed by agarose gel electrophoresis and sequenced using the
HiSeq 2000 system (Illumina, San Diego, CA). The average sequencing depth was
35 per sample (range, 35 to 37 ; s.d., 0.6 ).
Whole-exome sequencing. Genomic DNAs from patients 2 to 6 were sheared
into fragments with peaks of 150–200 bp, and then adapters were ligated to both
ends. The adapter-ligated templates were puriﬁed with Agencourt AMPure SPRI
beads (Beckman Coulter, Inc., Brea, CA), and fragments with an insert size of
B200 bp were excised. Extracted DNA was ampliﬁed by ligation-mediated PCR,
puriﬁed and hybridized to the SureSelect biotinylated RNA library (Agilent
Technologies, Santa Clara, CA) for enrichment according to the manufacturer’s
instructions. Paired-end multiplex sequencing of samples was performed with the
IlluminaHiSeq 2000 System. The average sequencing depth was 62 per sample
(range, 51 to 74 ; s.d., 9 ).
Sequence alignment and variant calling. Paired-end reads in FastQ format
generated by the Illumina pipeline were aligned to the reference human genome
(UCSC Genome Browser, version hg19) using the Burrows-Wheeler Aligner with
default settings38, except for a seed length of 40, a maximum edit distance of 3 and a
maximum edit distance in the seed of 2. Aligned reads were further processed
according to the Genome Analysis Toolkit (GATK) Best Practices
(www.broadinstitute.org/gatk/guide/best-practices.php) for duplicate removal, indel
realignment and base recalibration.
Both VarScan13 version 2.2.5 and MuTect14 were used to detect potential
single-nucleotide variations. For VarScan, in addition to the built-in ﬁlters, the
following ﬁltering criteria were applied: (i) coverage Z10 in germline DNA and
Z4 in tumour DNA; (ii) variant frequencyZ10%; and (iii) Po0.0001 for calling a
somatic site. For MuTect, in addition to the build-in ﬁlters, the following ﬁltering
criteria were applied: (i) total read count in tumour DNAZ15; (ii) total read count
in germline DNA Z6; (iii) presence of variant on both strands; (iv) variant allele
frequency in tumour DNA Z10%; (v) variant allele frequency in germline
DNA¼ 0; and (vi) removal of variants in positions listed in the dbSNP129 database
(www.ncbi.nlm.nih.gov/SNP/). Single-nucleotide variants called by either method
were used for further analysis (Supplementary Tables 2–4).
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The GATK SomaticIndelDetector39,40 was used to detect potential somatic
indels. The following ﬁltering criteria were applied: (i) read depth 45 in both
tumour and normal samples; (ii) average mismatch rate o0.5 in both normal and
mutant alleles; (iii) average mapping quality 420 in both normal alleles and
mutant alleles in a tumour; and (iv) median indel offsets from the end of the reads
45 bp (Supplementary Tables 2 and 3).
For samples from patient 1, which were subjected to WGS, the CREST
(Clipping Reveals Structure) algorithm41 was implemented to identify potential
structural variants. Only breakpoint pairs with at least ﬁve supporting clipped reads
spanning the breakpoints and at least one supporting clipped read for each end
were selected for validation and further analysis.
Somatic variant validation. Nonsynonymous coding and splice site mutations
called by either MuTect or VarScan were subjected to mass spectrometry or Sanger
sequencing for validation when adequate DNA was available. Mass spectrometry
was performed ﬁrst with the MassArray platform (Sequenom, San Diego, CA) as
previously described42. For mutations for which Sequenom software failed to
design primers for ampliﬁcation, Sanger sequencing was applied for validation.
Sanger sequencing was also used to validate structural variants.
Detection of SCNAs by microarray-based CGH. We performed SCNA analysis
using the Human Genome CGH Microarray Kit 244A (Agilent Technologies) with
8.9 kb overall median probe spacing, according to the ULS Labeling Protocol for
Agilent Oligonucleotide Array-Based CGH for Genomic DNA Analysis (version 3.4,
July 2012). After scanning with the Agilent Scanner System, the data in each slide
were extracted with Feature Extraction 12.0 (Agilent Technologies) for further
analysis. The extracted data were subjected to locally weighted scatterplot smoothing
to remove potential intensity and/or GC content bias before calculating the log2 copy
number ratios in reference to the matching normal. Log2 ratios for each tumour
sample were then segmented by applying the circular binary segmentation
algorithm43. Copy number gain was deﬁned as segmented log2 ratio40.3, and copy
number loss was deﬁned as log2 ratioo 0.3. Cancer genes known to be affected by
ampliﬁcation or deletion (http://cancer.sanger.ac.uk/cancergenome/projects/census/)
were also screened using these thresholds. Manual inspection was applied to review
all segments containing candidate genes in each tumour region to make
ampliﬁcation and deletion calls. We also assessed the clonal relationship between
different tumours based on the likelihood ratio against a background reference
distribution as previously described7. Brieﬂy, copy number segmentation data were
partitioned into overlapping regions across samples. Pair-wise correlations were
calculated for all potential pairs between as well as within tumours. Inter-tumour
correlations were plotted as the background distribution, and intratumour
correlations were plotted in shade. Finally, adjacent segments were merged and
annotated with recurrent copy number changes of lung adenocarcinomas
referenced in the TCGA Copy Number Portal (http://www.broadinstitute.org/tcga/
gistic/browseGisticByTissue;jsessionid=08F9235B734370DB93AF3A4A33D86DB9).
Segments overlapping with Z50% of the recurrently ampliﬁed or lost regions were
classiﬁed as gains or losses, respectively.
APOBEC mutation signature analysis. APOBEC mutation signatures were
analysed as previously described3. In brief, APOBEC signature enrichment ETCW in
relation to the strength of mutagenesis at the TCW motif (where W is either A or
T) was calculated as in equation (1):
ETCT ¼ mutationsTCWcontextCorGmutationsCorGcontextTCW ð1Þ
where mutationsTCW is the number of mutated cytosines (and guanines) in a TCW
(or WGA) motif, mutationsCorG is the total number of mutated cytosines (or
guanines), contextTCW is the total number of TCW (or WGA) motifs within a 41-
nucleotide region centred on the mutated cytosines (and guanines) and contextCorG
is the total number of cytosines (or guanines) within the 41-nucleotide region
centred on the mutated cytosines (or guanines). Only the following substitutions
were included in the analysis: TCW to TTW or TGW and WGA to WAA or WCA.
Overrepresentation of the APOBEC mutation signature was determined using a two-
sided Fisher’s exact test comparing the ratio of cytosine-to-thymine or cytosine-to-
guanine substitutions with guanine-to-adenine or guanine-to-cytosine substitutions
that occurred in and out of the APOBEC target motif (TCW or WGA) to an
analogous ratio for all cytosines and guanines inside and outside the TCW or WGA
motif within the 41-nucleotide region centred on the mutated cytosine or guanine.
Statistical analyses. Analysis of variance was used to assess the association
between mutation burden and the gender or smoking status of each patient. The
Pearson product–moment correlation test was used to assess the association
between mutation burden and each patient’s age or tumour size. The Fisher’s exact
test was used to assess the signiﬁcance of differences in mutation spectra between
different tumours, and the Pearson product–moment correlation analysis was used
to assess the correlation between the mutation spectra of different tumours. The
Fisher’s exact test was also used to compare the incidences of EGFR p.L858R in our
cohort and the Chinese lung adenocarcinoma cohort15. To determine the
correlation of SCNA proﬁles between different tumours from the same patients, we
processed segmented data using the Bioconductor CNTools software package to
generate a gene-by-tumour-region copy number matrix. Correlations between
different tumours were then calculated to obtain correlation coefﬁcients.
Data availability. Whole-genome and -exome sequencing data have been
deposited at the European Genome-phenome Archive (www.ebi.ac.uk/ega/),
which is hosted by the European Bioinformatics Institute (accession number:
EGAS00001001572). The aCGH data have been deposited in the GEO database
under accession code GSE86607. All other data are included within the Article or
Supplementary Information or available from the authors on request.
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